Independent specialist cancer care provider, GenesisCare, becomes first UK private cancer care provider, to offer Optune Gio® as their standard of care for newly diagnosed WHO Grade 4 Glioma patients, through their partnership with global oncology company, Novocure.
Eligible patients can access Optune Gio® as part of their treatment for WHO Grade 4 Glioma in a streamlined process which means they will no longer have to self-advocate to their insurer for this treatment.
Optune Gio® is a portable CE marked medical device. Optune Gio® delivers alternating electric fields, called Tumour Treating Fields (“TTFields”). TTFields are delivered at a unique frequency that allows it to selectively disrupt Grade 4 Glioma cell division¹²³. TTFields are delivered locally and non-invasively, directly at the tumour site via arrays that adhere to the skin.
A large phase 3 randomised controlled clinical trial showed that treatment with TTFields when used concomitantly with temozolomide (chemotherapy), extended median overall survival by 4.9months vs temozolomide alone without significantly compromising quality of life. Mild to moderate skin toxicity underneath the transducer arrays occurred in 52 per cent of the patients who received TTFields + temozolomide in the trial4.
Dr Anup Vinayan (pictured), Clinical Director for Neuro-oncology at GenesisCare, said: “Access has been the critical hurdle for newly diagnosed WHO Grade 4 Glioma patients.
“We’re incredibly proud that at GenesisCare, patients covered with major insurers such as Bupa and Aviva, will no longer have to self-advocate for Optune Gio®, as we now can offer it as our standard of care for eligible patients after completion of chemoradiation in one of our centres.”
“Novocure is committed to advancing treatment for some of the most aggressive forms of cancer and we look forward to working with the teams at GenesisCare who are focused on achieving the best outcomes for people living with newly diagnosed WHO Grade 4 Glioma,” said Hilary Duckworth, General Manager UK & Ireland, Novocure. “Through this partnership, we are able to provide our treatment to more patients due to GenesisCare’s unique network of care centres throughout the UK.”
For more information about GenesisCare visit www.genesiscare.com/uk
